Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:ATCCode |
A10AE04
|
| gptkbp:biosimilar |
gptkb:Lantus
|
| gptkbp:brand |
gptkb:insulin
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
gptkb:government_agency
|
| gptkbp:genericName |
gptkb:insulin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Semglee
|
| gptkbp:indication |
gptkb:diabetes_mellitus
|
| gptkbp:manufacturer |
gptkb:Biocon
gptkb:Mylan |
| gptkbp:marketedAs |
biosimilar insulin glargine
|
| gptkbp:powers |
100 units/mL
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:usedFor |
gptkb:type_2_diabetes
type 1 diabetes |
| gptkbp:bfsParent |
gptkb:insulin
gptkb:Lantus |
| gptkbp:bfsLayer |
6
|